Program
Eflornithine
Also written as “DFMO”, “Eflornithine (Dose Level 1)” and “Eflornithine (Dose Level 2)”.
Its studies are mostly in Adenomatous Polyposis Coli · Melanoma · Glioblastoma · Astrocytoma · Hirsutism, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cancer Prevention Pharmaceuticals | 30 open or running | phase 3since Nov 19, 2010 | Nov 19, 2010 | none ahead |
| Orbus Therapeutics | 21 open or running | phase 3since Jun 3, 2016 | Jun 3, 2016 | none ahead |
| AbbVie | 10 open or running | phase 4since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| Aminex Therapeutics | 11 open or running | phase 2since Nov 24, 2025 | Nov 24, 2025 | Feb 28, 2028phase 2 · NCT07287917 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 8, 2005First study: phase 4 study in HirsutismNew to AbbVieAbbVie · NCT00152048 · 78 enrolled
- Nov 19, 2010Cancer Prevention Pharmaceuticals's first study: phase 3 study in Adenomatous Polyposis ColiNew to Cancer Prevention PharmaceuticalsCancer Prevention Pharmaceuticals · NCT01245816
- Nov 21, 2011Phase 3 study in Adenomatous Polyposis ColiCancer Prevention Pharmaceuticals · NCT01483144 · 171 enrolled · United States, Belgium, Canada and more
- Jul 2, 2012Phase 2 study in NeoplasmsCancer Prevention Pharmaceuticals · NCT01636128
- Jun 3, 2016Orbus Therapeutics's first study: phase 3 study in AstrocytomaNew to Orbus TherapeuticsOrbus Therapeutics · NCT02796261 · 343 enrolled · United States, Belgium, Canada and more
- May 3, 2023Phase 1 study in GlioblastomaOrbus Therapeutics · NCT05879367 · 66 planned · United States
- Nov 24, 2025Aminex Therapeutics's first study: phase 2 study in MelanomaNew to Aminex TherapeuticsAminex Therapeutics · NCT07287917 · 92 planned · United States
Ahead
- Feb 28, 2028Primary completion: phase 2 study in MelanomaAminex Therapeutics · NCT07287917
TargetBeta
“Ornithine decarboxylase inhibitor”ChEMBL 37, by rule
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07287917Melanoma · United States | 2 | Recruiting | Aminex Therapeutics | Feb 28, 2028 | 92 |
| NCT05879367Glioblastoma · United States | 1 | Recruiting | Orbus Therapeutics | Jun 30, 2026 | 66 |
| NCT02796261Astrocytoma · United States, Belgium, Canada and more | 3 | UNKNOWN | Orbus Therapeutics | Jun 2023 | 343 |
| NCT01636128Neoplasms | 2 | Withdrawn | Cancer Prevention Pharmaceuticals | Mar 2016 | 0 |
| NCT01483144Adenomatous Polyposis Coli · United States, Belgium, Canada and more | 3 | Completed | Cancer Prevention Pharmaceuticals | Nov 2018 | 171 |
| NCT01245816Adenomatous Polyposis Coli | 3 | Withdrawn | Cancer Prevention Pharmaceuticals | May 2013 | 0 |
| NCT00152048Hirsutism | 4 | Completed | AbbVie | 78 |
How it is read
Names in the registry
- “Eflornithine”, 2 entries
- “DFMO”, 1 entry
- “Eflornithine (Dose Level 1)”, 1 entry
- “Eflornithine (Dose Level 2)”, 1 entry
- “Eflornithine (Dose Level -1)”, 1 entry
Conditions, from the studies’ own filings
- Adenomatous Polyposis Coli, 2 studies
- Melanoma, 1 study
- Glioblastoma, 1 study
- Astrocytoma, 1 study
- Hirsutism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.